Seminars in Radiation Oncology
Volume 18, Issue 2 , Pages 89-97, April 2008

Tissue Microarrays in Clinical Oncology

  • David Voduc, MD, FRCPC

      Affiliations

    • Department of Radiation Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada.
    • Corresponding Author InformationAddress reprint requests to David Voduc, MD, FRCPC, Department of Radiation Oncology, BC Cancer Agency, 600 West 10th Ave, Vancouver, BC, Canada V5Z 4E6.
    • ,
  • Challayne Kenney, BMLSc

      Affiliations

    • Genetic Pathology Evaluation Centre, Vancouver, British Columbia, Canada.
    • ,
  • Torsten O. Nielsen, MD, PhD, FRCPC

      Affiliations

    • Department of Pathology, University of British Columbia, Vancouver, British Columbia, Canada.

Tissue microarray (TMA) is a recently implemented, high-throughput technology for the analysis of molecular markers in oncology. This research tool permits the rapid assessment of a biomarker in thousands of tumor samples, using commonly available laboratory assays such as immunohistochemistry and in situ hybridization. Although introduced less than a decade ago, TMA has proven to be invaluable in the study of tumor biology, the development of diagnostic tests, and the investigation of oncologic biomarkers. This review describes the impact of TMA-based research in clinical oncology and its potential future applications. Technical aspects of TMA construction and the advantages and disadvantages inherent to this technology are also discussed.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 David Voduc and Torsten O. Nielsen are supported by the National Institutes of Health Strategic Partnering to Evaluate Cancer Signatures program. Torsten O. Nielsen is a scholar of the Michael Smith Foundation for Health Research. The Genetic Pathology Evaluation Centre is supported by an unrestricted educational grant from sanofi-aventis.

PII: S1053-4296(07)00097-5

doi:10.1016/j.semradonc.2007.10.006

Seminars in Radiation Oncology
Volume 18, Issue 2 , Pages 89-97, April 2008

Article Tools

* Image Usage & Resolution